1. EU restrictions for quinolone antibacterials due to serious ADRs

   News item 01 December 2018 Pages: 1 - 1

2. Mylan's valsartan products banned from EU medicines

   News item 01 December 2018 Pages: 2 - 2

3. Post-approval studies in US are "vital to enhancing patient safety"

   News item 01 December 2018 Pages: 3 - 3

4. UK's MHRA launches third social media campaign

   News item 01 December 2018 Pages: 4 - 4

5. US FDA warns that stopping Gilenya can worsen MS

   News item 01 December 2018 Pages: 5 - 5

6. Adverse events contribute to costs of metastatic melanoma

   Meeting report 01 December 2018 Pages: 6 - 6

7. Adverse events on social media

   Meeting report 01 December 2018 Pages: 7 - 7

8. Canadian drug safety database holds valuable information

   Epidemiology population study 01 December 2018 Pages: 8 - 8

9. Cutaneous reactions with psychotropic drugs

   Clinical study 01 December 2018 Pages: 9 - 9

10. Drugs that can kill a toddler with one dose

    Clinical study 01 December 2018 Pages: 10 - 10

11. Higher than expected ADR rates with immune checkpoint inhibitors

    Clinical study 01 December 2018 Pages: 11 - 11

12. Major congenital malformations following antiemetic exposure

    Clinical study 01 December 2018 Pages: 12 - 12

13. ACE inhibitors/alteplase

    Case report 01 December 2018 Pages: 13 - 13

14. Aciclovir

    Case report 01 December 2018 Pages: 14 - 14

15. Aciclovir/enalapril

    Case report 01 December 2018 Pages: 15 - 15

16. Acitretin

    Case report 01 December 2018 Pages: 16 - 16

17. Afatinib

    Case report 01 December 2018 Pages: 17 - 17

18. Alectinib/ceritinib/crizotinib

    Case report 01 December 2018 Pages: 18 - 18

19. Alectinib/crizotinib

    Case report 01 December 2018 Pages: 19 - 19

20. Alemtuzumab

    Case report 01 December 2018 Pages: 20 - 20

21. Alemtuzumab

    Case report 01 December 2018 Pages: 21 - 21

22. Alemtuzumab/ganciclovir

    Case report 01 December 2018 Pages: 22 - 22

23. Algestone acetophenide/estradiol/medroxyprogesterone

    Case report 01 December 2018 Pages: 23 - 23

24. Alglucosidase α

    Case report 01 December 2018 Pages: 24 - 24

25. Alitretinoin

    Case report 01 December 2018 Pages: 25 - 25

26. Amikacin/rifampicin

    Case report 01 December 2018 Pages: 26 - 26

27. Amiodarone/lercanidipine/rivaroxaban interaction

    Case report 01 December 2018 Pages: 27 - 27

28. Amisulpride/gastrokinetics/ranitidine

    Case report 01 December 2018 Pages: 28 - 28

29. Amlodipine

    Case report 01 December 2018 Pages: 29 - 29

30. Amoxicillin/cetirizine/NSAID

    Case report 01 December 2018 Pages: 30 - 30

31. Amoxicillin/clavulanic-acid

    Case report 01 December 2018 Pages: 31 - 31

32. Amoxicillin/metronidazole/omeprazole

    Case report 01 December 2018 Pages: 32 - 32

33. Amphotericin-B liposomal/antiretrovirals

    Case report 01 December 2018 Pages: 33 - 33

34. Amrubicin

    Case report 01 December 2018 Pages: 34 - 34

35. Anti-epileptics

    Case report 01 December 2018 Pages: 35 - 35

36. Antibacterials

    Case report 01 December 2018 Pages: 36 - 36

37. Antineoplastics

    Case report 01 December 2018 Pages: 37 - 37

38. Antineoplastics

    Case report 01 December 2018 Pages: 38 - 38

39. Antineoplastics

    Case report 01 December 2018 Pages: 39 - 39

40. Antineoplastics

    Case report 01 December 2018 Pages: 40 - 40

41. Antineoplastics

    Case report 01 December 2018 Pages: 41 - 41

42. Antineoplastics

    Case report 01 December 2018 Pages: 42 - 42

43. Antineoplastics

    Case report 01 December 2018 Pages: 43 - 43

44. Antineoplastics/epirubicin/immunosuppressants

    Case report 01 December 2018 Pages: 44 - 44

45. Antineoplastics/rituximab

    Case report 01 December 2018 Pages: 45 - 45

46. Antineoplastics/streptozocin

    Case report 01 December 2018 Pages: 46 - 46

47. Antiparkinsonians

    Case report 01 December 2018 Pages: 47 - 47

48. Antipsychotics/Methylphenidate

    Case report 01 December 2018 Pages: 48 - 48

49. Antituberculars

    Case report 01 December 2018 Pages: 49 - 49

50. Antituberculars

    Case report 01 December 2018 Pages: 50 - 50